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The ability of transferrin to potentiate oxygen free 
radical-mediated endothelial cell injury was assessed. 
“Cr-labeled endothelial cells derived from rat pulmonary 
arteries (RPAECs) were incubated with hydrogen per- 
oxide (H20z) in the presence and absence of holosaturated 
human transferrin, and the effect of transferrin on H,Oz- 
mediated endothelial cell toxicity was determined. Ad- 
dition of holosaturated transferrin potentiated HaOz- 
mediated RPAEC cytotoxicity at concentrations of I&O2 
greater than 10 pM, suggesting that transferrin may pro- 
vide a source of iron for free radical-mediated endothelial 
cell injury. Free radical-mediated injury is dependent on 
non-protein-bound iron. The ability of RPAECs to facil- 
itate the release of iron from transferrin was assessed. 
We determined that RPAECs facilitate the release of 
transferrin-derived iron by reduction of transferrin- 
bound ferric iron (Fe”) to ferrous iron (Fe2’). The re- 
duction and release of transferrin-derived Fe” were in- 
hibited by apotransferrin and chloroquine, indicating a 
dependence on receptor-specific binding of transferrin 
to the RPAEC cell surface, with subsequent endocytosis, 
acidification, and reduction of transferrin-bound Fe’+ to 
Fe’+. The release of transferrin-derived Fe2+ was poten- 
tiated by diethyldithiocarbamate, an inhibitor of intra- 
cellular superoxide dismutase (SOD). In contrast, exog- 
enous SOD did not alter iron release, suggesting that 
intracellular superoxide anion (0;) may play an impor- 
tant role in mediating the reduction and release of trans- 
ferrin-derived iron. Results of this study suggest that 
transferrin may provide a source of iron for oxygen free 
radical-mediated endothelial cell injury and identifi a 
novel mechanism by which endothelial cells may medi- 
ate the reduction and release of transferrin-derived iron. 
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Free radical-mediated endothelial cell injury is depen- 
dent on the presence of ionic iron (1). Iron promotes cell 
injury by its ability to catalyze hydroxyl radical (OH) 
formation via a Fenton reaction and by peroxidation of 
unsaturated lipids. Under normal physiological condi- 
tions, iron is bound to iron-binding proteins and is unable 
to participate in biological reactions in this bound state. 
Transferrin is the primary iron-binding protein in the 
vertebrate bloodstream. Iron (Fe3+) is normally bound to 
transferrin in a ternary complex involving iron, transfer- 
rin, and bicarbonate (2-6). A most challenging question 
in transferrin chemistry is identification of mechanisms 
by which transferrin is induced to release iron (7). Re- 
duction of transferrin-bound ferric iron (Fe3’) to ferrous 
iron (Fe’+), which binds weakly to transferrin, is one 
mechanism by which iron is released (3,4,8). The results 
of previous investigations suggest that both hepatocytes 
and polymorphonuclear leukocytes (PMNs)~ promote the 
reduction and release of transferrin-derived iron at the 
cell surface, although by different mechanisms. Hepato- 
cyte plasma membranes have been reported to contain 
an NADH diferric transferrin reductase which facilitates 
the transfer of electrons from intracellular NADH to 
plasma membrane-bound transferrin, resulting in the re- 
lease of transferrin-derived Fe2+ (9), while PMNs generate 
extracellular superoxide anion (O,-) , which, under acidic 
conditions, facilitates the reduction and release of trans- 
ferrin-derived iron (10). 
The results of recent investigations suggest that a 
source of iron for free radical-mediated endothelial cell 
injury is the endothelial cell itself (1). Endothelial cells 
have previously been shown to have cell surface receptors 
for transferrin (11). Theoretically, transferrin-derived 
* Abbreviations used: PMNs, polymorphonuclear leukocytes; RPARCs, 
rat pulmonary artery endothelial cells; FBS, fetal bovine serum; HBSS, 
Hanks’ balanced salt solution; BPS, bathophen anthroline disulfonic 
acid; NTA, nitrilotriacetic acid; PBS, phosphate-buffered saline; BSA, 
bovine serum albumin; TD buffer, Tris-salt buffer; SOD, superoxide 
dismutase; X0, xanthine oxidase; DDC, diethyldithiocarbamate. 
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iron could potentiate free radical-mediated endothelial 
cell toxicity. The ability of endothelial cells to mediate 
the release of iron from transferrin has not been thor- 
oughly investigated. In the following investigation, the 
effect of transferrin on oxygen free radical-mediated en- 
dothelial cell cytotoxicity was assessed. The ability of en- 
dothelial cells to facilitate the release of iron from trans- 
ferrin was also studied. A novel mechanism by which 
endothelial cells may mediate the reduction and release 
of transferrin-derived iron, thereby providing a source of 
non-protein-bound iron for oxidant-mediated endothelial 
cell injury, was identified. 
MATERIALS AND METHODS 
Chemicals. All chemicals were obtained from Sigma Chemical Com- 
pany (St. Louis, MO) unless otherwise noted. 
Endothelial cells. Endothelial cells from rat pulmonary arteries 
(RPAECs) (the generous gift of Dr. James Varani and Dr. Sem Phan, 
University of Michigan Medical School, Ann Arbor) were obtained as 
previously described (12). RPAECs were used between passages 24 and 
31. Cells were maintained in monolayer cultures in DMEM-F12 sup- 
plemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and 
100 U/ml penicillin, streptomycin, and fungizone. Cells were passaged 
by mechanical scraping without exposure to proteases. Growth was at 
37’C and 5% COZ. Stocks were kept frozen in liquid nitrogen. Unless 
otherwise described, for studies using intact RPAECs, cells were sub- 
cultured in 35-mm 6-well culture dishes (Costar) in DMEM-F12 with 
0.8% FBS, 2 mM glutamine, and 100 U/ml of penicillin, streptomycin, 
and fungizone at 1300 cells/cm’. Cells were grown to confluent mono- 
layers (7-9 days). For collection of endothelial cell plasma membranes, 
endothelial cells were plated at the same density and medium in T150 
culture flasks and grown to confluence as described above. 
Cytotoxicity assay. Cytotoxicity was measured using a ‘iCr-release 
assay as previously described (1, 13). Briefly, RPAECs (3.3 X 10’ cells/ 
ml) were added to wells of a 24-well culture dish in 1 ml of culture 
medium containing 2 pCi of NaWrO,. RPAECs were incubated over- 
night (37”C, 5% COs) and washed three times with Hanks’ balanced 
salt solution (HBSS), pH 7.4, to remove unincorporated radioactivity. 
Appropriate reactants [H,Oz (O-50 PM) + holosaturated human trans- 
ferrin (60 PM)] were added to wells in a final volume of 1 ml of HBSS 
per well. After incubation at 37°C for 4 h, the culture supernatant was 
removed from each well and centrifuged (3OOg, 10 min, 4’0, and 0.5 
ml was assayed to determine 61Cr release (Tm Analytic, Elk Grove Vil- 
lage, IL). Spontaneous release of slCr from endothelial cells was deter- 
mined from wells incubated with HBSS in the absence of additional 
reactants. Total 51Cr release was determined from wells incubated in 
0.1% Triton X-100. Cytotoxicity was calculated from the percentage of 
specific Wr release by the formula 
% cytotoxicity = 
experimental release - spontaneous release 
total release - spontaneous release 
x 100. 
In selected experiments, holosaturated human transferrin was initially 
dialyzed against 0.1 M sodium perchlorate (NaCIOI) as described pre- 
viously (14) to remove any contaminating iron and dialyzed against 
HBSS prior to use. 
Release of Fe2’ from h&saturated human transferrin. The reduction 
of diferric transferrin by RPAECs was measured by the formation of 
the ferrous bathophenanthroline disulfonate (Fez+. BPS) complex (3). 
Briefly, confluent RPAEC monolayers in 6-well plates were incubated 
in 1 ml of HBSS (pH 7.4) containing holosaturated human transferrin 
(O-60 pM) and BPS (0.50 mM), an extracellular Fe’+ chelator (14), for 
one 1 h at 37’C. The reduction and release of transferrin-derived Fez+ 
were determined spectrophotometrically by the change in absorbance 
(AU) at 535 nm of RPAEC-conditioned medium using a Cary 210 spec- 
trophotometer (Varion, Inc., Palo Alto, CA). The lower limit of AU 
change that can be measured accurately under conditions in these ex- 
periments is 0.001. The change in absorbance of RPAEC-conditioned 
medium divided by the extinction coefficient of the Fe2+ * BPS complex 
(2.214 X ld M-’ cm-i) yields nanomoles of Fe’+ released from diferric 
transferrin. Results are expressed as nanomoles of Fe2+ released/lo’ 
RPAECs/60 min. In selected experiments, the effect of specific inhibitors 
on RPAEC-mediated release of transferrin-derived Fe*+ was determined. 
For these experiments, RPAECs were preincubated with the inhibitors 
(37°C) prior to addition of transferrin (60 pM) and BPS (0.50 mM). The 
concentration of specific inhibitors used and the duration of the prein- 
cubation were as follows: apotransferrin (60 pM, 20 min), superoxide 
dismutase (30 U/ml, 10 min), adriamycin (1O-6 M, 20 min), diethyldi- 
thiocarbamate (0.1 mM, 20 min), oxypurinol (1 mM, 45 min), rotenone 
(0.050 mM, 20 min), and chloroquine (1 mM, 20 min). The dosage and 
time of incubation were chosen based on previous studies demonstrating 
effectiveness of the compounds in endothelial cells or other cellular sys- 
tems (9, 10, 15-23). 
Preparation of transferrin at physiological levels of iron satura- 
tion. Transferrin, at physiological levels of iron saturation (i.e., 30- 
60%), was made according to previously published methods (10, 23) 
with minor modifications. A 0.2 mu Fe3+ stock solution was prepared 
by reacting Fe3+ with nitrilotriacetic acid (NTA) at a ratio of 1:4 (23). 
Sideroferrin (60 pM final) in 0.01 M Tris buffer (pH 7.4) was incubated 
with Fe. NTA (0.040-0.072 mM final) in the presence of sodium bicar- 
bonate (NaHCO,, 10 mM final) for 30 min at 22°C. The percentage iron 
saturation of transferrin was determined by comparison of the change 
in absorbance at 470 nm of the solution to that of holosaturated trans- 
ferrin (60 PM). The partially iron-saturated transferrin was dialyzed in 
PBS (pH 7.4) containing NaClO, for 24 h to chelate any extraneous 
iron (14). The transferrin solution containing NaC104 was dialyzed 
against PBS for 12 h, concentrated in an Amicon concentrator, and 
dialyzed against HBSS (pH 7.4) for 12 h. The protein content of the 
partially iron-saturated transfer& was assessed via the Bradford protein 
assay with bovine serum albumin (BSA) as a standard (24). Partially 
iron-saturated transferrin was then utilized in assays previously described 
for holosaturated human transferrin. 
Purification of RPAECplusmu membranes. Plasma membranes were 
isolated from intact RPAECs on Cytodex-1 microcarrier beads (25). 
Cultured RPAECs were removed from T150 flasks by mechanical scrap- 
ing. The cells and microcarrier beads were washed three times in at- 
tachment buffer consisting of 7 vol of 310 mM sucrose and 3 vol of a 
310 mOsm solution of sodium acetate (pH 5.2). The beads and cells 
were then combined in 20 ml of attachment buffer and incubated together 
for 15 min on ice. The microcarrier beads, with adherent endothelial 
cells, were centrifuged (4OOg, 10 min, 4°C) and the supernatant was 
discarded. Adherent cells were then lysed by incubating the microcarrier 
beads with 0.1 N NaOH (pH 8.0). The beads, with adherent RPAEC 
plasma membranes, were centrifuged (4OOg, 10 min, 4°C) and the su- 
pernatant was discarded. RPAEC plasma membranes were stripped from 
Cytodex-1 beads by incubation of microcarrier beads in 0.2 M borate 
buffer and 0.2 M NaCl (pH 9.8) for 10 min. The sample was centrifuged 
(4OOg, 10 min, 4’C) and the microcarrier beads were discarded. The 
supernatant containing RPAEC plasma membranes was concentrated 
over an Amicon PM-10 filter. Protein content of concentrated RPAEC 
plasma membranes was determined using the Bradford protein assay 
with bovine serum albumin as a standard (24). 
NADH diferric transferrin reductase activity in RPAECplnsmn mem- 
branes. NADHdiferrictransferrinreductaseactivityinRPAECplasma 
membranes was assayed by measuring the formation of Fe2+ * BPS and 
the oxidation of NADH in the presence of diferric transferrin (26). The 
reduction of transferrin-derived iron by isolated plasma membranes was 
determined by formation of the Fe *+a BPS complex following incubation 
of RPAEC plasma membranes with transferrin and NADH (3, 27). 
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FIG. 1. Effect of transferrin on H,O,-mediated RPAEC cytotoxicity. 
51Cr-labeled RPAECs (3.3 X 10’) were incubated with HxO, (O-50 FM) 
in the absence or presence of holosaturated human transferrin (60 PM) 
for 4 h at 37°C. The effect of transferrin on H,Ox-mediated RPAEC 
cytotoxicity was determined. A, HxO,; n , H202 + transferrin. *Signifi- 
cantly different than HxO, alone (P < 0.05). 
Briefly, RPAEC plasma membranes (0.030 mg protein) were incubated 
in a final volume of 2.8 ml in Tris-salt (TD) buffer (25 mM Trizma base, 
140 mM NaCl, 5 mM KCl, 0.6 mu NaxPOI, pH 7.4) containing BPS (10 
pM) and NADH (25 PM) and the change in absorbance of the sample 
was recorded using a dual-beam spectrophotometer (535 nm-600 nm). 
Holosaturated human diferric transferrin (10 PM) was added to the re- 
action and the change in AU of the sample was determined. The change 
in AU following addition of transferrin minus the change in AU in the 
absence of transferrin, divided by the extinction coefficient (17.6 
mM-‘cm-i), yields nanomoles of Fe*+ released from transferrin per min- 
ute per milligram of RPAEC plasma membrane. Transferrin-dependent 
oxidation of NADH by RPAEC plasma membranes was monitored 
spectrophotometrically in a dual-beam spectrophotometer at 340 nm- 
430 nm. RPAEC plasma membranes (0.030 mg) in a final volume of 2.8 
ml were incubated in 0.05 mM sodium phosphate buffer (pH 7.4) con- 
taining 1 mM KCN and 25 pM NADH and the change in absorbance of 
the sample was assessed. Holosaturated human transferrin (10 PM) was 
then added to the reaction and the oxidation of NADH monitored spec- 
trophotometrically as described above. The change in AU of the sample 
in the presence of transferrin minus the change in AU in the absence 
of transferrin, divided by the extinction coe5cient (6.22 mW’ cm-i), 
yields nanomoles of NADH oxidized per minute per milligram of RPAEC 
plasma membrane. 
Statistical analysis. All data represent the means f SEM for at least 
three experiments. Student’s paired t test was used to compare differences 
between treatment groups. P < 0.05 was considered significant. 
RESULTS 
The ability of transferrin to potentiate oxidant-me- 
diated endothelial cell injury was determined (Fig. 1). In 
agreement with previous reports (13) the addition of HzOz 
to RPAEC cultures potentiated endothelial cell toxicity 
in a dose-dependent manner. Addition of holosaturated 
human transferrin (60 PM) significantly enhanced HzOz- 
mediated RPAEC cytotoxicity at concentrations of Hz02 
greater than 10 PM (Fig. 1). Dialysis of holosaturated hu- 
man transferrin in 0.1 M NaC104 prior to use did not 
significantly alter this effect of transferrin on HzO,-me- 
olc. ” I ” ” a. ‘. . ’ 
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FIG. 2. Effect of transferrin concentration on the reduction and release 
of transferrin-derived Fe*+ by RPAECs. RPAECs were incubated with 
holosaturated human transfer& (O-120 pM) and the effect of transferrin 
concentration on the release of transferrin-derived Fe’+ was determined. 
diated RPAEC injury (data not shown). These results 
indicate that holosaturated human transferrin potentiates 
oxygen free radical-mediated endothelial cell cytotoxicity. 
Protein-bound iron is not able to facilitate free radical- 
mediated injury. However, incubation of intact RPAECs 
with holosaturated transferrin resulted in the reduction 
and release of transferrin-derived Fe2+ (Fig. 2). The 
amount of Fe2+ released was proportional to the concen- 
tration of transferrin in the reaction (Fig. 2) and to the 
duration of incubation of intact RPAECs with transferrin 
(Fig. 3). Maximum Fe2+ release was observed at 0.060 mM 
transferrin (Fig. 2) and occurred only after a 30-min la- 
tent period, rapidly approaching a maximum at 60 min 
(Fig. 3). 
Intravascular transferrin is normally only partially iron 
saturated (28). Therefore, the ability of RPAECs to fa- 
0 20 40 60 53 
TIME (MINUTES) 
FIG. 3. Effect of duration of incubation on the reduction and release 
of transferrin-derived Fez+ by RPAECs. RPAECs ( 106) were incubated 
with holosaturated human transferrin (60 pM) for O-60 min and the 
effect of duration of incubation of transferrin with RPAECs on the 
release of transferrin-derived Fe2+ was determined. Results are expressed 
as percentage iron released compared with nanomoles of Fe’+ released/ 
lo6 RPAECs/GO min. 
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cilitate the reduction and release of iron from partially 
iron-saturated (30-60%) transferrin was assessed. Results 
of these investigations (data not shown) indicate that 
RPAECs are unable to promote the release of detectable 
amounts of iron from partially (~60%) iron-saturated 
transferrin. In subsequent experiments, the mechanism 
by which RPAECS facilitate the release of iron from ho- 
losaturated transferrin was investigated. The release of 
transferrin-derived iron by other cells, including hepa- 
tocytes and HeLa cells, has previously been shown to be 
dependent on transferrin binding to cell surface receptors 
(9, 18). Endothelial cells also have cell surface receptors 
for transferrin (11). To determine if the release of trans- 
ferrin-derived Fe2+ by RPAECs was dependent on trans- 
ferrin binding to cell surface receptors, intact RPAECs 
were preincubated with apotransferrin (Fig. 4) and the 
effect on the release of transferrin-derived iron was as- 
sessed. Preincubation of RPAECs with apotransferrin 
inhibited the release of transferrin-derived Fe2+ by 95% 
(P < 0.02). These results indicate that the release of Fez+ 
from holosaturated human transferrin by intact RPAECs 
is dependent, at least in part, on transferrin binding to 
transferrin receptors on the RPAEC cell surface. 
Previous studies indicate that the reduction and release 
of transferrin-derived Fe2+ by liver cells and HeLa cells 
(9) is due to a cell membrane-associated NADH diferric 
transferrin reductase. This enzyme functions as a trans- 
membrane electron transport, transferring electrons from 
intracellular NADH to transferrin bound iron, generating 
Fe’+ (9). To determine if a similar electron transport sys- 
tem exists in RPAECs, RPAEC plasma membranes were 
purified and assessed for the presence of NADH diferric 
transferrin reductase activity (see Materials and Meth- 
ods). Neither the release of transferrin-derived Fe2+ nor 
the transferrin-dependent oxidation of NADH by isolated 
RPAEC plasma membranes (data not shown) was de- 
tected. Furthermore, incubation of intact RPAECs with 
adriamycin, an inhibitor of NADH diferric transferrin 
reductase activity in HeLa cells and hepatocyte plasma 
membranes (16), failed to inhibit the reduction and release 
of transferrin-derived iron (Fig. 4). These results indicate 
that RPAEC plasma membranes lack NADH diferric 
transferrin reductase activity, suggesting that RPAECs 
mediate the reduction and release of transferrin-derived 
iron by an alternative mechanism. 
Alternatively, phagocytic cells, including human PMNs, 
generate extracellular superoxide anion (O,-), which, un- 
der acidic conditions, has been shown to reduce transfer- 
rin-bound Fe3+ to Fe2+ (10). The reduction and release of 
transferrin-derived iron by PMNs are inhibited by in- 
cubation of PMNs with superoxide dismutase (SOD) (10). 
Endothelial cells have previously been shown to produce 
0; (25,26). To determine if RPAEC-derived extracellular 
0; facilitates the reduction and release of transferrin- 
derived iron, the amount of extracellular 0; generated by 
RPAECs was determined. Results of these experiments 
ADR CHLORO ROT DDC APO SOD Oxy 
FIG. 4. Effect of inhibitors on the reduction and release of transferrin- 
derived iron by RPARCs. RPAECs were preincubated with inhibitors 
[apotransferrin (APO), 60 pM, 20 min; superoxide dismutase (SOD), 30 
U/ml, 10 min; adriamycin (ADR), lOa M, 20 miq diethyldithiocarbamate 
(DDC), 0.1 mM, 20 min; oxypurinol (OXY), 1 mu, 45 min; rotenone 
(ROT), 0.050 mM, 20 min; and chloroquine, (CHLORO), 1 mu, 20 min] 
and the effect of the inhibitors on the reduction and release of transferrin- 
derived iron was determined. Results are expressed as percentage Fe*+ 
released compared with nanomoles of Fer+ released/lo6 RPARCs/60 
min in the absence of inhibitors. *Significantly less than control (P < 
0.05). 
indicate that lo6 RPAECs spontaneously generate ap- 
proximately 0.6 nmol extracellular 0,/h. In subsequent 
experiments, RPAECs were preincubated with SOD and 
the effect of SOD on the reduction of diferric transferrin 
was determined (Fig. 4). Incubation of RPAECs with SOD 
did not inhibit the release of transferrin-derived Fe’+, in- 
dicating that the release of transferrin-derived iron by 
RPAECs is not mediated by extracellular 0;. 
Many cells, including endothelial cells, also generate 
0, intracellularly, due to production of oxygen radicals 
by subcellular components including mitochondria (30- 
33), endoplasmic reticulum (32), and cytoplasmic enzymes 
including xanthine oxidase (X0) (29, 34). Theoretically, 
the reduction of transferrin-derived iron by RPAECs 
could be mediated by intracellular 0;. To determine if 
intracellular 0, facilitates the reduction and release of 
transferrin-derived Fe2+, RPAECs were incubated with 
diethyldithiocarbamate (DDC), a potent inhibitor of the 
cytoplasmic Cu-Zn superoxide dismutase (CuZn-SOD, 
[35,36]). As shown in Fig. 4, incubation of RPAECs with 
DDC enhanced the release of transferrin-derived Fe2+ 
greater than fivefold. Because DDC has previously been 
shown to be a modestly good reducing agent (37), the 
ability of DDC to facilitate the reduction of iron bound 
to transferrin in the absence of cells was determined. Re- 
sults of these experiments indicate that DDC (0.1 mM) 
does facilitate the release of relatively small amounts of 
Fe2+ from transfer& (0.22 nmol Fe2+/0.060 mM trans- 
ferrin/h). However, approximately 35-fold more Fe2+ is 
released when RPAECs that have been preincubated with 
DDC are incubated with transferrin (Fig. 4). These results 
suggest that the reduction and release of transferrin-de- 
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rived iron by RPAECs are mediated, at least in part, by 
intracellular 0;. 
While several subcellular components can generate ox- 
ygen free radicals, results of recent reports indicate that 
a significant amount of free radical generation by endo- 
thelial cells is due to X0 activity (20, 27). To determine 
the role of endothelial cell-derived X0 in the release of 
transferrin-derived Fe2+, RPAECs were incubated with 
oxypurinol [a potent inhibitor of X0 (ZO)] and the effect 
on the release of transferrin-derived Fe2+ was determined 
(Fig. 4). Incubation of RPAECs with oxypurinol, at con- 
centrations previously shown to inhibit RPAEC X0 ac- 
tivity (20), failed to significantly inhibit the reduction 
and release of iron from transferrin indicating that X0 
is an unlikely source of intracellular 0; for reduction of 
diferric transferrin. Mitochondrial respiratory chain 
components also generate O;, due to the formation of 
semiquinones, which spontaneously oxidize producing 
intramitochondrial 0; (21). To assess the possible role 
of mitochondria-derived 0, in the reduction of transfer- 
rin-bound iron, RPAECs were incubated with rotenone 
which inhibits the mitochondrial respiratory chain and 
induces maximal rates of 0; generation (21). Incubation 
of RPAECs with rotenone did not significantly enhance 
the release of transferrin-derived Fe2+ by RPAECs (Fig. 
4). Furthermore, it has previously been shown that 0; 
does not efficiently permeate the phospholipid bilayer of 
intact mitochondria (21). Therefore, the reduction of 
transferrin-derived iron by RPAECs is not likely to be 
mediated by mitochondria-derived 0;. 
The uptake of iron by mammalian cells involves 
receptor-mediated endocytosis and internalization of 
the transferrin-transferrin receptor complex (38), fol- 
lowed by labilization of transferrin-bound iron in an 
intracellular acidic vesicle. Acidification of transferrin 
potentiates the labilization of its iron, due to hydro- 
gen ion-induced changes in the conformation of the 
Fe3+ * transferrin * bicarbonate complex. These confor- 
mational changes in transferrin result in a decreased 
binding affinity of transferrin for iron (2, 22,39,40) and 
increased susceptibility of the iron to reduction. To de- 
termine the potential role of endocytosis and acidification 
on the release of transferrin-derived Fe2+, RPAECs were 
preincubated with chloroquine, which both affects uptake 
of extracellular ligands to endosomes (41, 42) and in- 
creases the intracytoplasmic pH (16, 43-45). Incubation 
of RPAECs with chloroquine significantly inhibits the 
release of transferrin-derived Fe2+ (Fig. 4), indicating an 
important role of endocytosis and vesicle acidification in 
the labilization of transferrin-derived iron by RPAECs. 
DISCUSSION 
Previous investigations have suggested that iron derived 
from endothelial cells is critical for oxygen free radical- 
mediated endothelial cell injury (1). Results of this study 
indicate that transferrin potentiates oxygen free radical- 
mediated endothelial cell cytotoxicity. Furthermore, 
RPAECs promote the release of detectable amounts of 
iron from holosaturated but not from partially iron sat- 
urated human transferrin. The inability of RPAECs to 
promote the release of detectable amounts of iron from 
partially iron saturated transferrin may be due, at least 
in part, to the differences in binding affinity of the two 
transferrin iron binding sites, resulting in enhanced af- 
finity of partially iron-saturated transferrin for iron rel- 
ative to holosaturated transferrin (46). The mechanism 
by which RPAECs potentiate the reduction and release 
of transferrin-derived iron was investigated. Results of 
these experiments indicate that the release of transferrin- 
derived iron by RPAECs is dependent on transferrin 
binding, followed by endocytosis and acidification of 
transferrin, because apotransferrin and chloroquine re- 
spectively inhibited the reaction. Incubation of RPAECs 
with DDC potentiated the reduction and release of iron 
from transferrin, suggesting that endocytosed transferrin 
is reduced by intracellular 0,) resulting in the release of 
Fe2+. Although xanthine oxidase (X0) has previously been 
identified as an intracellular source of 0; in endothelial 
cells (20, 27), incubation of RPAECs with oxypurinol 
failed to significantly inhibit the release of iron from 
transferrin. These results suggest that alternative sources 
of intracellular O;, which mediate the release of trans- 
ferrin-derived Fe2+, must be examined. The existence of 
additional pathways for intracellular 0; production in 
endothelial cells is supported by previous reports which 
show that incubation of endothelial cells with oxypurinol 
fails to totally inhibit 0; production (27). 
In summary, a possible sequence of events resulting in 
oxygen free radical-mediated endothelial cell injury in uiuo 
identified by these in vitro experiments is as follows. At 
an inflammatory focus there is destruction of the endo- 
thelial barrier resulting in the extravasation of serum 
proteins, including transferrin, red blood cells, and leu- 
kocytes into the inflammatory site. While intravascular 
transferrin is normally only partially iron saturated (28), 
it has previously been shown that, where there is signif- 
icant hemorrhage, the iron binding capacity of extravas- 
cular transferrin can approach 100% (47). Holosaturated 
human transferrin, present at the inflammatory focus, 
binds to transferrin receptors on the endothelial cell sur- 
face and is endocytosed into acidic endosomes in the en- 
dothelial cell. Within the endosomes, transferrin-bound 
ferric iron is labilized (due to the acidity of the endosomal 
environment) and is therefore more susceptible to reduc- 
tion. The labilized, transferrin-derived iron is subse- 
quently reduced to Fe*+ by 0; generated intracellularly 
in RPAECs by an as of yet unidentified mechanism. Sub- 
sequent reaction of the reduced non-protein-bound iron 
with hydrogen peroxide and lipid hydroperoxides gener- 
ated by activated phagocytes at the inflammatory focus 
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could result in the generation of reactive hydroxyl (OH’) 22. 
and lipid radicals and subsequent free radical-mediated 
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